Beyond Air, Inc. reported a 105% year-over-year revenue increase to $2.2 million, driven by widespread adoption of LungFit PH system in over 45 hospitals. Customer retention exceeds 90%, with over half secured under multiyear agreements. Operating expenses reduced by 36%, with focus on high-priority hospitals for Gen I adoption and Gen II launch preparations.

The FDA decision on the second-generation LungFit PH system is expected by the end of 2026, pending regulatory review and inspections. The Gen II system aims to expand market reach with transport compatibility. Cash burn is projected to decrease as revenue grows, with current resources supporting operations through 2027 and potentially to profitability.

Beyond Air secured financing and an equity line of credit to support commercial readiness. Gen II system reliability testing surpassed 3,000 hours, expected to triple service interval and improve gross margins. Management highlighted the importance of VA sales and Gen II positioning for transport-heavy requirements.

Management anticipates Gen II system to enhance gross margins through lower service requirements. Gen I margins expected to stabilize at 50% to 60%. Completion of work at the contract manufacturer is the primary gating factor for FDA inspection. High confidence expressed in the timeline with no major regulatory hurdles.

Read more at Yahoo Finance: Beyond Air, Inc. Q3 2026 Earnings Call Summary